Status:
COMPLETED
The Effects of OC000459 on Nasal Mediators
Lead Sponsor:
Trevor Hansel
Collaborating Sponsors:
Oxagen Ltd
Conditions:
Allergic Rhinitis
Eligibility:
MALE
18-50 years
Phase:
PHASE1
PHASE2
Brief Summary
This is the first proof of concept study for OC000459 and is undertaken to assess the effects of the compound on the development of inflammatory cytokines in a model (nasal allergen challenge model) t...
Eligibility Criteria
Inclusion
- 1\. Males aged 18 to 50 years with a history of symptoms of grass pollen related allergic rhinitis within the previous two years.
Exclusion
- 1\. Medical conditions likely to affect the outcome of the study.
- 2 History of immunotherapy in the past 3 years or currently on an immunotherapy treatment course including inhaled or local corticosteroids in the past 28 days.
- 3\. Any infirmity, disability, or geographic location which, in the opinion of the principal investigator, would limit compliance with the protocol.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00290381
Last Update
October 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Heart & Lung Institute Clinical Studies Unit
London, United Kingdom, SW3 6HP